Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, immunogenicity and clinical efficacy of an allergen vaccine (AllQbG10) in subjects with allergic rhino-conjunctivitis and asthma due to house dust mite allergy

Trial Profile

Safety, immunogenicity and clinical efficacy of an allergen vaccine (AllQbG10) in subjects with allergic rhino-conjunctivitis and asthma due to house dust mite allergy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Apr 2008

At a glance

  • Drugs CYT 005 AllQbG10 (Primary)
  • Indications Asthma; Rhinoconjunctivitis
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Cytos Biotechnology
  • Most Recent Events

    • 26 Apr 2008 New trial record.
    • 14 Dec 2005 Primary endpoint 'Immunological response' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top